{"id":249805,"date":"2023-09-08T00:00:00","date_gmt":"2023-09-08T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0075-biopharma-non-alcoholic-fatty-liver-disease-epidemiology\/"},"modified":"2026-05-06T11:14:51","modified_gmt":"2026-05-06T11:14:51","slug":"epidmd0075-biopharma-non-alcoholic-fatty-liver-disease-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0075-biopharma-non-alcoholic-fatty-liver-disease-epidemiology-mature-markets\/","title":{"rendered":"Non-Alcoholic Fatty Liver Disease &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of nonalcoholic fatty liver disease (<abbr title=\"nonalcoholic fatty liver disease\">NAFLD<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr title=\"nonalcoholic fatty liver disease\">NAFLD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and Europe and 10 years for the other countries we cover.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"nonalcoholic fatty liver disease\">NAFLD<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"nonalcoholic fatty liver disease\">NAFLD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology provides at least 10 years of forecast data for the following subpopulation:<\/p>\n<ul class=\"round-bullets\">\n<li>Obesity status.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-249805","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249805\/revisions"}],"predecessor-version":[{"id":281386,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249805\/revisions\/281386"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}